Angiogenic factor levels across severity stages of fetal smallness with or without associated pre-eclampsia


Por: Youssef, L, Paolucci, S, Crovetto, F, Miranda, J, Lobmaier, S, Figueras, F, Crispi, F and Gratacos, E

Publicada: 1 feb 2026 Ahead of Print: 1 ene 2026
Resumen:
Objective Angiogenic factors are elevated in fetal growth restriction (FGR), but their clinical value for assessing the severity of FGR and the potential influence of coexisting pre-eclampsia has scarcely been investigated. In this study, our aim was to investigate the profile of maternal angiogenic factors across severity stages of fetal smallness compared with controls, analyzed overall and stratified by the presence or absence of pre-eclampsia, and to investigate whether values of these angiogenic factors, such as placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and the sFlt-1/PlGF ratio, are helpful in determining the severity stage of fetal smallness. Methods This was a prospective cohort study of women with a singleton pregnancy diagnosed with fetal smallness (defined as birth weight < 10th centile) (n = 604) between October 2010 and December 2017, compared with a control group of pregnant women with an appropriate-for-gestational-age (AGA) singleton fetus (defined as birth weight >= 10th centile) (n = 424). At diagnosis, ultrasound was performed to assess estimated fetal weight (EFW) and Doppler pulsatility indices (PI) of the uterine artery (UtA), umbilical artery (UA), fetal middle cerebral artery (MCA) and ductus venosus (DV), and these parameters were monitored regularly until delivery. Cerebroplacental ratio (CPR) was calculated as MCA-PI/UA-PI. Small fetuses were classified as: small-for-gestational age (SGA) if EFW >= 3rd and < 10th centile, with normal Doppler parameters; FGR Stage I if either EFW < 3rd centile, persistent MCA-PI < 5th centile, UA-PI > 95th centile, CPR < 5th centile or UtA-PI > 95th centile; FGR Stage II if there was absent end-diastolic flow in the UA; FGR Stage III if there was reversed end-diastolic flow in the UA or DV-PI >= 95th centile; or FGR Stage IV if there was non-reassuring cardiotocography or absent/reversed DV atrial flow. Maternal peripheral venous blood concentrations of PlGF and sFlt-1 were determined using enzyme-linked immunosorbent assay, and the sFlt-1/PlGF ratio was calculated. Linear trend of proportions was tested using the Mantel-Haenszel chi-square test. Results Among AGA controls (n = 424), SGA (n = 192), FGR Stage I (n = 380), FGR Stage II (n = 16) and FGR Stages III-IV (n = 16) fetuses, the proportion of cases with a sFlt-1/PlGF ratio > 95th centile was 12.7%, 7.8%, 30.8%, 43.8% and 62.5%, respectively (P = 0.0001), and the median multiples of the median (MoM) values for the sFlt-1/PlGF ratio were 0.55 (interquartile range (IQR), 0.19-2.00), 1.00 (IQR, 0.31-2.67), 3.03 (IQR, 0.91-8.20), 3.94 (IQR, 0.85-9.13) and 7.32 (IQR, 1.44-16.29), respectively (P = 0.24). Pre-eclampsia was diagnosed at any time between inclusion and delivery in 1.9% of controls, 3.6% of SGA, 21.1% of FGR Stage I, 37.5% of FGR Stage II and 50.0% of FGR Stages III-IV fetuses. Among all small fetuses with vs without pre-eclampsia, the proportion of pregnancies with sFlt-1/PlGF ratio > 95th centile was 56.9% vs 15.4% (P < 0.001) and the median MoM of the sFlt-1/PlGF ratio was 8.11 (IQR, 3.83-27.09) vs 1.59 (IQR, 0.52-5.04) (P = 0.18). Conclusions Serum levels of angiogenic factors became more abnormal as the severity stage of fetal smallness increased. This association with severity was stronger in the presence of pre-eclampsia. However, absolute values of serum levels showed substantial overlap in both the presence and the absence of pre-eclampsia, making their use in determining the severity stage of fetal smallness challenging. (c) 2026 International Society of Ultrasound in Obstetrics and Gynecology.

Filiaciones:
:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

 Univ Barcelona Campus, Hosp Clin, Josep Carreras Leukaemia Res Inst, Barcelona, Spain

Paolucci, S:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

 Univ Insubria, Osped Filippo Ponte, Dept Obstet & Gynecol, Varese, Italy

Crovetto, F:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

 Fundacio St Joan Deu, Inst Recerca St Joan Deu IRSJD, Barcelona, Spain

Miranda, J:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

 Univ Cartagena, Grp Invest Cuidado Intens & Obstet GRICIO, Fac Med, Dept Obstet & Gynecol, Cartagena, Colombia

 Ctr Hosp Serena Mar, Dept Obstet & Gynecol, Bogota, Colombia

 Fdn Santa Fe Bogota, Bogota, Colombia

Lobmaier, S:
 Tech Univ Munich, Munich, Germany

 TUM Sch Med, Dept Obstet & Gynecol, Munich, Germany

Figueras, F:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

Crispi, F:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

 Ctr Biomed Res Rare Dis CIBER ER, Madrid, Spain

Gratacos, E:
 Univ Barcelona, Hosp Clin, Barcelona Ctr Maternal Fetal & Neonatal Med, BCNatal, Barcelona, Spain

 Univ Barcelona, Hosp St Joan Deu, IDIBAPS, Barcelona, Spain

 Fundacio St Joan Deu, Inst Recerca St Joan Deu IRSJD, Barcelona, Spain

 Ctr Biomed Res Rare Dis CIBER ER, Madrid, Spain
ISSN: 14690705





ULTRASOUND IN OBSTETRICS & GYNECOLOGY
Editorial
John Wiley & Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 67 Número: 2
Páginas: 147-154
WOS Id: 001656522700001
ID de PubMed: 41505741
imagen Bronze

MÉTRICAS